The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
RYSTIGGO (UCB Australia Pty Ltd T/A UCB Pharma Division of UCB Australia)
Product name
RYSTIGGO
Date registered
Evaluation commenced
Decision date
Approval time
204 (255 working days)
Active ingredients
rozanolixizumab
Registration type
NCE/ NBE
Indication
Rystiggo is indicated as an add-on to standard therapy for the treatment of generalised myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive.